Most Read Articles
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 4 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Nocturnal hypertension in high-risk mid-pregnancies predicts pre-eclampsia/eclampsia

11 Jan 2019

A recent study suggests that nocturnal hypertension at high-risk mid-pregnancy is common and strongly predicts pre-eclampsia/eclampsia (PEEC). Such risk was two times higher in women not taking acetylsalicylic acid (ASA).

Eighty-seven women (mean age 31±7 years) with 23±2 weeks of pregnancy were included in the study. The corresponding prevalence of office and ambulatory blood pressure monitoring (ABPM) hypertension was 13.8 percent and 40.2 percent. There was a low concordance between these two diagnoses of hypertension (κ, 0.170; p=0.044).

Nocturnal hypertension was more frequent than diurnal hypertension (35.6 percent vs 26.4 percent). Nocturnal hypertension significantly elevated the relative risk of PEEC (odds ratio [OR], 5.32; 95 percent CI, 1.48–19.10).

PEEC risk associated with diurnal hypertension was not statistically significant. When both diurnal and nocturnal hypertension were included in the same model, only the latter significantly predicted PEEC (p=0.012). Furthermore, women not taking ASA had higher relative risk attributed to nocturnal hypertension (OR, 11.40; 2.35–55.25).

Women coursing high-risk mid-pregnancies participated in this study, which sought to test whether hypertension detected by ABPM was a useful predictor for PEEC. Office BP, taken by a specialized nurse after a 15-min interview, was estimated as the mean of three values. Office hypertension was defined as 140/90 mm Hg. An ABPM was initiated immediately after.

Diurnal hypertension referred to ABPM 135/85 mm Hg during daily activities, while nocturnal hypertension was defined as ABPM 120/70 mm Hg during night rest. The investigators used logistic regression to estimate the adjusted PEEC risk.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 4 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
2 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.